B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-25Clinical Trial Update: BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating a CD19-targeting CAR-T cell therapy with BCOR and ZC3H12 gene knock-outs for relapsed/refractory B-…
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study at the University of Chicago assessing pembrolizumab plus chemotherapy for untreated B-…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating U01(ssCART-19) for B-cell lymphoma is ongoing. The study is currently recruiting at Shanghai Tongji Ho…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 study evaluating CD19/CD22 CAR T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B cell maligna…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma [Phase 1]
Phase 1 trial evaluating a triple-targeted CD19/CD20/CD22 cell therapy for relapsed/refractory B-cell lymphoma was terminated. The study sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-05-13Clinical Trial Update: A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies [Phase 1]
A Phase I trial of donor-derived 19-28z CAR T cells following allogeneic transplant for CD19 malignancies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-06Clinical Trial Update: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL [Phase 1]
Phase 1 trial evaluating PD-1, LAG-3, and TIM-3 checkpoint blockade for diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies [Phase 1]
This is a Phase 1 clinical trial update on CD22-directed CAR T cells for children and young adults with B-cell malignancies, including B-cel…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: CD-19 CAR-T Cell for Pediatric ALL or Lymphoma [NA]
Clinical trial update for a CD-19 CAR-T cell therapy being investigated for pediatric acute lymphoblastic leukemia and pediatric lymphoma; t…
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies [Phase 1]
Phase 1 study of XS-04 in relapsed or refractory hematologic malignancies, including B-cell lymphoma, acute myeloid leukemia, and myelodyspl…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma [NA]
A CD30-targeted CAR-T therapy is being studied for CD30-positive relapsed/refractory lymphoma. The trial is currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 trial of CD19 t-haNK for diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating CAR2219 CAR-T cells for relapsed or refractory B-cell leukemia and B-cell lymphoma is currently recrui…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating chidamide in combination with linperlisib for refractory/relapsed follicular lymphoma is currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: Phase Ib Clinical Study of Keynatinib [Phase 1]
A Phase Ib study of Keynatinib for B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update indicates Sepantronium bromide is being studied for high-grade B-cell lymphomas, with the study currently ac…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluating safety and efficacy of a fourth-generation CAR-T therapy for hematologic malignancies, including multipl…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating CD19 and CD22 bispecific CAR T cells for relapsed/refractory B-cell hematologic tumors, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: CAR-37 T Cells in Hematologic Malignancies [Phase 1]
Phase 1 trial update on CAR-37 T cells in hematologic malignancies shows the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies [Phase 1]
A Phase 1 study of the bispecific antibody MCLA-145 in adults with advanced or metastatic malignancies has completed enrollment.
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]
Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, sp…
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial update on the combination of rituximab and varlilumab immunotherapy in patients with B-cell lymphoma, now completed.
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma [Phase 2]
A Phase 2 clinical study evaluating TQB3702 tablets with immunochemotherapy for B-cell lymphoma is currently recruiting.